The Benefits and Harms of Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator Within 6 H of Acute Ischaemic Stroke (The Third International Stroke Trial [IST-3]): A Randomised Controlled Trial

Study Questions:

What are the benefits and harms of thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) in patients who do not exactly meet the license criteria for its use (especially elderly patients), and would a wider range of patients benefit from this treatment?